Fast Stochastic
Previous Close | 4.95 |
Open | 4.97 |
Bid | 5.02 x 1800 |
Ask | 5.04 x 800 |
Day's Range | 4.82 - 5.14 |
52 Week Range | 2.50 - 9.49 |
Volume | |
Avg. Volume | 2,938,411 |
Market Cap | 640.784M |
Beta (5Y Monthly) | 2.62 |
PE Ratio (TTM) | N/A |
EPS (TTM) | -2.26 |
Earnings Date | Aug 01, 2023 - Aug 07, 2023 |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | N/A |
1y Target Est | 11.00 |
CAMBRIDGE, Mass., May 30, 2023--Seres Therapeutics, Inc. (Nasdaq: MCRB), a leading microbiome therapeutics company, today announced that the Company has received a $125 million milestone payment from Nestlé Health Science related to the U.S. Food and Drug Administration approval of VOWST™ (fecal microbiota spores, live-brpk), an orally administered microbiota-based therapeutic to prevent recurrence of C. difficile Infection (CDI) in adults following antibiotic treatment for recurrent CDI.
Flagship Pioneering, the bioplatform innovation company, today announced the launch of Metaphore Biotechnologies, a company harnessing the power of biomimicry and machine learning to unlock the transformative therapeutic potential of functional molecular mimics. Two years into development, Flagship has made an initial commitment of $50 million to advance Metaphore's MIMiC™ platform and build its pipeline for patients with autoimmune, metabolic, or oncology indications.
CAMBRIDGE, Mass., May 10, 2023--Seres Therapeutics, Inc. (Nasdaq: MCRB) ("Seres" or the "Company"), a leading microbiome therapeutics company, today announced that on May 3, 2023, the Compensation and Talent Committee of Seres’ board of directors granted inducement equity grants covering an aggregate of 19,000 shares of its common stock to four new employees, consisting of stock options to purchase an aggregate of 11,000 shares of common stock and restricted stock units ("RSUs"), covering an agg
Seres Therapeutics (MCRB) delivered earnings and revenue surprises of 0% and 126.10%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?
CAMBRIDGE, Mass., May 09, 2023--Seres Therapeutics, Inc. (Nasdaq: MCRB), a leading microbiome therapeutics company, today reported first quarter 2023 financial results and provided business updates.
CAMBRIDGE, Mass., May 09, 2023--Seres Therapeutics, Inc. (Nasdaq: MCRB), a leading microbiome therapeutics company, today reported initial clinical data about SER-155. SER-155 is an oral, cultivated bacterial consortia investigational therapeutic designed to prevent enteric-derived infections and resulting blood stream infections, as well as induce immune tolerance responses to reduce the incidence of graft-versus-host disease (GvHD) in patients undergoing allogeneic hematopoietic stem cell tran
CAMBRIDGE, Mass. & HOBOKEN, N.J., May 08, 2023--Seres Therapeutics, Inc. (Nasdaq: MCRB), and Nestlé Health Science today announced the presentation of data from the Phase 3 open-label ECOSPOR IV study evaluating VOWST (fecal microbiota spores, live-brpk) – the first and only U.S. Food and Drug Administration (FDA)-approved orally administered microbiota-based therapeutic for the prevention of recurrence in adults with recurrent C. difficile (rCDI) following antibacterial treatment. VOWST is not
By Vlad Schepkov
CAMBRIDGE, Mass., May 05, 2023--Seres Therapeutics, Inc. (Nasdaq: MCRB), a leading microbiome therapeutics company, today announced that management will host a conference call and live audio webcast on May 9, 2023 at 8:30 a.m. ET to discuss first quarter results and provide a general business update, including initial SER-155 Phase 1b safety and pharmacology results from study Cohort 1.
Key Insights Significantly high institutional ownership implies Seres Therapeutics' stock price is sensitive to their...
Alector (ALEC) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
CAMBRIDGE, Mass., April 27, 2023--Seres Therapeutics, Inc. (Nasdaq: MCRB), a leading microbiome therapeutics company, today announced that it has entered into a new $250 million senior secured debt facility ("Term Loan Facility") provided by funds managed by Oaktree Capital Management, L.P. ("Oaktree"). The Company drew the first tranche of $110 million at closing, with three additional tranches available. These additional tranches include $90 million that will be available in two tranches of $4
The approval of Seres' microbiome drug took 12 years. Here's a timeline of major milestones and setbacks along the way.
CAMBRIDGE, Mass. & HOBOKEN, N.J., April 26, 2023--Seres Therapeutics, Inc. (Nasdaq: MCRB) and Nestlé Health Science today announced the U.S. Food and Drug Administration (FDA) approval of VOWSTTM (fecal microbiota spores, live-brpk), formerly called SER-109, an orally administered microbiota-based therapeutic to prevent recurrence of C. difficile Infection (CDI) in adults following antibacterial treatment for recurrent CDI (rCDI). VOWST is not indicated for the treatment of CDI.
The U.S. health regulator on Wednesday approved Seres Therapeutics Inc's pill for treating a type of bacterial infection, giving an easier and standardized option to patients who often have to rely on individual donors for fecal transplants. The drug, branded as Vowst, was approved for treating 18 years and older for recurrent Clostridioides difficile (C. diff) infections (CDI), generally caused by prolonged use of antibiotics, which wipe out friendly colon bacteria and can cause potentially fatal diarrhea and inflammation of the colon. Vowst consists of a certain kind of bacteria made by purifying fecal matter derived from healthy people, while fecal transplants are donated by healthy volunteers and are not purified.
Seres Therapeutics (MCRB) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
By Vlad Schepkov
After a dreadful 2022, growth stocks have started to rebound in 2023. The tech-heavy Nasdaq Composite has gained a healthy 15.4% so far this year. For example, Wall Street analysts think small-cap biotechs Iovance Biotherapeutics (NASDAQ: IOVA) and Seres Therapeutics (NASDAQ: MCRB) could see a parabolic rise in their respective share prices in 2023.
Seres Therapeutics (MCRB) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
Arrowhead Pharmaceuticals and Seres Therapeutics are screaming buys, according to some Wall Street analysts.
Seres Therapeutics (MCRB) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
CAMBRIDGE, Mass., March 09, 2023--Seres Therapeutics, Inc. (Nasdaq: MCRB), a leading microbiome therapeutics company, today announced that Eric Shaff, President and Chief Executive Officer of Seres Therapeutics, will provide a corporate presentation at the Oppenheimer 33rd Annual Healthcare Conference on Wednesday, March 15, 2023 at 8:40 a.m. ET.
Seres Therapeutics, Inc. (NASDAQ:MCRB) Q4 2022 Earnings Call Transcript March 7, 2023 Operator: Thank you for holding, and welcome everyone, to the Seres Therapeutics Fourth Quarter 2022 Conference Call. . Thank you. I will now turn the call over to Dr. Carlos — Carlo Tanzi of Investor Relations. Dr. Carlo Tanzi, please go ahead. Carlo […]
Q4 2022 Seres Therapeutics Inc Earnings Call
Seres Therapeutics (MCRB) delivered earnings and revenue surprises of -31.71% and 89.21%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?